论文部分内容阅读
冠状动脉粥样硬化性心脏病（ CHD）是一种严重威胁人类健康的疾病，现已成为心力衰竭（HF）的主要病因。血清γ－谷氨酰转肽酶（GGT）作为一种抗氧化剂，在体内主要参与谷胱甘肽的代谢，是诊断肝胆疾病及酒精性肝病的一项重要指标，其在 CHD 中的研究也取得了一定的进展。 GGT与CHD的发生、发展机制密切相关，其在CHD及HF的预后监测中起重要作用，现已成为 CHD新的标志物，为CHD的预防和治疗提供了新的靶点。“,”Coronary heart disease(CHD) has now become the main cause of heart failure(HF) threat-ening human health with rising mortality.As an important enzyme in glutathione metabolism,glutamyl trans-ferase (GGT) is widely used in the diagnosis of liver and gallbladder diseases,especially in alcoholic liver disease.Moreover,GGT has shown to be involved in the development of CHD,which plays an important role in the prognosis monitoring of CHD and HF.GGT has now become a new biomarker of CHD,and may provide new preventive and therapeutic target of CHD.